Pay in 4 interest-free payments of $7.23 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Introduction If you've started noticing more hair in the shower drain or on your pillow since beginning a GLP-1 medication like Ozempic (semaglutide), Wegovy (semaglutide), Mounjaro (tirzepatide), or Zepbound (tirzepatide), you are not imagining it, and you are not alone
A 2025 Cochrane review of tirzepatide for adults with obesity also did not flag insomnia as a common adverse event, which lines up with what most patients experience in clinical practice
A medication can reduce appetite, but it does not automatically protect muscle, correct nutrient gaps, or remove the need for follow-up
Pieber , 9 more and Edward John Pratt 5,773 views 3 citations Review 21 May 2025 The evolution of the therapeutic concept GIP receptor antagonism Frederikke Koefoed-Hansen , 4 more and Lrke Smidt Gasbjerg 10,451 views 7 citations Review 17 March 2025 The role of GIPR in food intake control Paula-Peace James-Okoro , 2 more and Frank Reimann 12,710 views 11 citations Review 03 February 2025 The agony and the efficacy: central mechanisms of GLP-1 induced adverse events and their mitigation by GIP Jonathan D
Written by Content Writer Reviewed by Chief Clinical Officer Opioid Addiction Drug and Alcohol February 10, 2025
, ,
